benserazide has been researched along with Melanoma in 4 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levodopa has been shown to be a safe pharmacologic agent even after long-term usage." | 2.35 | Levodopa. ( Yahr, MD, 1975) |
| "Four of the patients had similar pharmacokinetic patterns for L-dopa and a significant (P < 0." | 1.30 | L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma. ( Dizdar, N; Granérus, AK; Hannestad, U; Kågedal, B; Kullman, A; Ljungdahl, A; Olsson, JE, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, Y | 1 |
| Huang, Z | 1 |
| Su, J | 1 |
| Li, J | 1 |
| Zhao, S | 1 |
| Wu, L | 1 |
| Zhang, J | 1 |
| He, Y | 1 |
| Zhang, G | 1 |
| Tao, J | 1 |
| Zhou, J | 1 |
| Chen, X | 1 |
| Peng, C | 1 |
| Dizdar, N | 1 |
| Granérus, AK | 1 |
| Hannestad, U | 1 |
| Kullman, A | 1 |
| Ljungdahl, A | 1 |
| Olsson, JE | 1 |
| Kågedal, B | 1 |
| Yahr, MD | 1 |
| Wick, MM | 1 |
| Kramer, RA | 1 |
| Gorman, M | 1 |
1 review available for benserazide and Melanoma
| Article | Year |
|---|---|
Levodopa.
Topics: Benserazide; Drug Interactions; Hepatic Encephalopathy; Humans; Huntington Disease; Levodopa; Melano | 1975 |
3 other studies available for benserazide and Melanoma
| Article | Year |
|---|---|
Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment.
Topics: Animals; Antineoplastic Agents; Benserazide; Carrier Proteins; Cell Growth Processes; Cell Line, Tum | 2020 |
L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma.
Topics: Aged; Antiparkinson Agents; Benserazide; Female; Humans; Levodopa; Male; Melanoma; Microdialysis; Mi | 1999 |
Enhancement of L-dopa incorporation into melanoma by dopa decarboxylase inhibition.
Topics: Adrenal Medulla; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Catecholamines; | 1978 |